12/06/2026
Researchers at the Harry Perkins Institute of Medical Research, led by Ciara Duffy, have discovered that melittin, the main active component of bee venom, can rapidly destroy certain aggressive breast cancer cells under laboratory conditions. Their study found that melittin was particularly effective against triple-negative breast cancer and HER2-positive breast cancer, two forms of the disease that can be difficult to treat. The compound disrupted cancer cell membranes within about an hour while showing relatively limited effects on normal healthy cells in laboratory experiments.
In Cancer Biology and Pharmacology, researchers are increasingly investigating natural compounds as potential sources of new therapies. The study also found that melittin enhanced the effectiveness of certain chemotherapy drugs, suggesting it could potentially be used alongside existing treatments to improve their ability to target resistant tumor cells.
Scientists believe melittin works by punching holes in cancer cell membranes and disrupting signaling pathways involved in tumor growth and survival. This targeted action has generated interest because many conventional cancer treatments can also damage healthy tissues, leading to significant side effects.
However, researchers emphasize that these findings are still at an early stage. The experiments were conducted primarily on cancer cells in the laboratory and animal models. Before melittin could become a medical treatment, it would need to undergo extensive testing through animal studies and human clinical trials to determine its safety, effectiveness, dosage, and potential side effects.
The research highlights how compounds evolved in nature for defense can sometimes provide valuable leads for medicine. While bee venom is not a cure for cancer, studies like this demonstrate the potential of natural bioactive molecules to inspire future targeted therapies for complex diseases.
Science Department |